BioCentury | Oct 31, 2011
Company News

Impel Neuropharm Inc. deal

...be delivered via a non-invasive intranasal device to the CNS, bypassing the blood-brain barrier. Impel Neuropharm...
BioCentury | Mar 31, 2011
Distillery Techniques

Technology: Disease models

...Therapeutics Inc. has arbaclofen (STX209) in Phase II testing for ASDs and Fragile X syndrome. Neuropharm Group plc...
BioCentury | Oct 4, 2010
Product Development

Dissipating a Slow Torture

...STX107 from Seaside Therapeutics Inc. is in Phase I for fragile X, and NPL-2009 from Neuropharm Group plc...
...Switzerland AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Michael J. Fox Foundation , New York, N.Y. Neuropharm Group plc...
BioCentury | May 10, 2010
Financial News

Neuropharm completes warrant exercise

Neuropharm Group plc (LSE: NPH), Leatherhead, U.K. Business: Neurology Date completed: 4/30/10 Type: Warrant exercise Raised: £60,000 ($91,482) Shares: 1.2 million Price: 5p Shares after offering: 32.7 million Investors: Individual investors WIR Staff Neurology...
BioCentury | Apr 26, 2010
Company News

Neuropharm neurology news

...inhibitor (SSRI), which uses Zydis drug delivery technology from Catalent Pharma Solutions Inc. (Somerset, N.J.). Neuropharm Group plc...
BioCentury | Nov 9, 2009
Company News

Neuropharm neurology news

...Neuropharm retained Piper Jaffray Ltd. to advise on a sale or merger of the biotech. Neuropharm...
...was in negotiations that may or may not lead to a sale of the company. Neuropharm...
...an update on the negotiations no later than at its annual general meeting Dec. 9. Neuropharm's...
BioCentury | Feb 23, 2009
Clinical News

NPL-2008: Phase III data

...was not disclosed. The compound was well tolerated with no serious adverse events. Last year, Neuropharm...
...complete the submission next quarter. The company did not disclose its plans for the compound. Neuropharm...
...Orphan designations in the U.S. to treat autism. Catalent Pharma Solutions Inc. , Somerset, N.J. Neuropharm Group plc...
BioCentury | Feb 23, 2009
Finance

Ebb & Flow

...to start Phase III testing mid-year. The ceramide analog inhibits glucosylceramide synthase (see B12) . Neuropharm...
...the Phase III SOFIA trial to treat autism showed that NPL-2008 missed the primary endpoint. Neuropharm...
BioCentury | Jan 12, 2009
Finance

2009 milestones

...Submit NDA 2H09 Neurobiological (NASDAQ:NTII) Viprinex ancrod Acute ischemic stroke Final Ph III data Mid-2009 Neuropharm...
BioCentury | Dec 8, 2008
Clinical News

NPL-2008: Extension study started

...developed using the Zydis delivery technology from Catalent. Catalent Pharma Solutions Inc. , Somerset, N.J. Neuropharm Group plc...
Items per page:
1 - 10 of 28
BioCentury | Oct 31, 2011
Company News

Impel Neuropharm Inc. deal

...be delivered via a non-invasive intranasal device to the CNS, bypassing the blood-brain barrier. Impel Neuropharm...
BioCentury | Mar 31, 2011
Distillery Techniques

Technology: Disease models

...Therapeutics Inc. has arbaclofen (STX209) in Phase II testing for ASDs and Fragile X syndrome. Neuropharm Group plc...
BioCentury | Oct 4, 2010
Product Development

Dissipating a Slow Torture

...STX107 from Seaside Therapeutics Inc. is in Phase I for fragile X, and NPL-2009 from Neuropharm Group plc...
...Switzerland AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Michael J. Fox Foundation , New York, N.Y. Neuropharm Group plc...
BioCentury | May 10, 2010
Financial News

Neuropharm completes warrant exercise

Neuropharm Group plc (LSE: NPH), Leatherhead, U.K. Business: Neurology Date completed: 4/30/10 Type: Warrant exercise Raised: £60,000 ($91,482) Shares: 1.2 million Price: 5p Shares after offering: 32.7 million Investors: Individual investors WIR Staff Neurology...
BioCentury | Apr 26, 2010
Company News

Neuropharm neurology news

...inhibitor (SSRI), which uses Zydis drug delivery technology from Catalent Pharma Solutions Inc. (Somerset, N.J.). Neuropharm Group plc...
BioCentury | Nov 9, 2009
Company News

Neuropharm neurology news

...Neuropharm retained Piper Jaffray Ltd. to advise on a sale or merger of the biotech. Neuropharm...
...was in negotiations that may or may not lead to a sale of the company. Neuropharm...
...an update on the negotiations no later than at its annual general meeting Dec. 9. Neuropharm's...
BioCentury | Feb 23, 2009
Clinical News

NPL-2008: Phase III data

...was not disclosed. The compound was well tolerated with no serious adverse events. Last year, Neuropharm...
...complete the submission next quarter. The company did not disclose its plans for the compound. Neuropharm...
...Orphan designations in the U.S. to treat autism. Catalent Pharma Solutions Inc. , Somerset, N.J. Neuropharm Group plc...
BioCentury | Feb 23, 2009
Finance

Ebb & Flow

...to start Phase III testing mid-year. The ceramide analog inhibits glucosylceramide synthase (see B12) . Neuropharm...
...the Phase III SOFIA trial to treat autism showed that NPL-2008 missed the primary endpoint. Neuropharm...
BioCentury | Jan 12, 2009
Finance

2009 milestones

...Submit NDA 2H09 Neurobiological (NASDAQ:NTII) Viprinex ancrod Acute ischemic stroke Final Ph III data Mid-2009 Neuropharm...
BioCentury | Dec 8, 2008
Clinical News

NPL-2008: Extension study started

...developed using the Zydis delivery technology from Catalent. Catalent Pharma Solutions Inc. , Somerset, N.J. Neuropharm Group plc...
Items per page:
1 - 10 of 28